BeOne Medicines Publishes Clinical Trial Portfolio Presentation

Bitget2026/11/05 11:28

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BeOne Medicines published its Q3 2026 clinical trials portfolio presentation.
Sonrotoclax holds U.S. approval for relapsed or refractory mantle cell lymphoma; an EU submission has been accepted.
Phase 3 trials of sonrotoclax in relapsed or refractory blood cancers remain enrolling.
Tacabrutideg’s Phase 3 trial against pirtobrutinib in relapsed or refractory CLL/SLL is enrolling 500 patients.
New pivotal programs include B7-H4 ADC in first-line ovarian cancer maintenance and GPC3-targeted therapy in second-line or later liver cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BeOne Medicines Publishes Clinical Trial Portfolio Presentation

You may also like

Crypto prices